Abstract
Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States.
Highlights
RESEARCH LETTEROut-of-Pocket Costs for SGLT-2 (SodiumGlucose Transport Protein-2) Inhibitors in the United States
Because of these effects, understanding the out-ofpocket costs for SGLT-2 inhibitors is essential
Medical Expenditure Panel Survey (MEPS) is Institutional Review Board approved by the Westat Institutional Review Board
Summary
Out-of-Pocket Costs for SGLT-2 (SodiumGlucose Transport Protein-2) Inhibitors in the United States. SGLT-2 (sodium-glucose transport protein-2) inhibitors are indicated for millions of US individuals with heart disease, diabetes, or kidney dysfunction.[1,2] these medications have a high retail price, at over $500 per month ($16 per pill).[3] The high costs may contribute to physician inertia to prescribe therapy, impede early initiation, and decrease patient adherence.[3,4]. Of these individuals, 58.0% had private insurances, 9.9% had Medicare, 7.3% had Medicaid only, 4.4% had dual Medicare/Medicaid, 14.4% had Medicare with private supplemental insurance, 2.4% had other insurances, and 3.6% had no insurance. Circulation: Heart Failure is available at www.ahajournals.org/journal/circheartfailure
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
